BTN3A activating mAb for IO


About this program

ICT01 targets BTN3A (also known as CD277), which is physiologically expressed on the surface of innate and adaptive immune cells (including T and NK cells). Furthermore, BTN3A is found overexpressed on a number of solid tumors (e.g., PDAC, breast cancer, gastric, ovarian) and blood cancers (e.g., AML). BTN3A is essential for the activation of the anti-tumor activity of γ9δ2 T cells in response to the intracellular accumulation of phosphoantigens (pAgs), a set of small organic pyrophosphates produced both by stressed cells (i.e., malignant or infected cells).

ICT01 is an activating mAb targeting the extracellular domain of BTN3A that leads to activation and trafficking of γ9δ2 T cells out of the circulation.  ICT01 has been shown to promote an anti-tumor immune response against a range of cancers in in vitro and in mouse tumor models. In primates, ICT01 rapidly occupies its target and specifically activates γ9δ2 T cells with a good safety profile that supports clinical testing.

Mechanism of action


Clinical development: Study ICT01-101

ImCheck Therapeutics has successfully completed CTA/IND-enabling studies and plans to launch the first-in-human clinical study ICT01-101 in early 2020.

ICT01 Clinical Advisory Board

Marc Bonneville, DVM, PhD
CSO of Institut Merieux
Former Director of the INSERM Cancer Research Center Nantes

Richard Buller, MD, PhD
Independent Consultant, Oncology Diagnostic and Drug Development Consulting, LLC
Former VP Oncology Clinical Development, Pfizer

Johann de Bono, MD, PhD
Head of Division on Clinical Studies at the Institute of Cancer Research, London
Director of Drug Development Unit and Head of Prostate Cancer Targeted Therapy Group

Aurélien Marabelle, MD, PhD
Clinical Director, Cancer Immunotherapy Program at Gustave Roussy

Daniel Olive, MD, PhD
Head of the Cancer Research Center Marseille
Professor of Immunology and Head of the Oncology Research Program at Aix Marseille University
Scientific Founder of ImCheck

ImCheck’s first clinical trial starting in 2020

Paul Frohna MD, PhD, PharmD

Chief Medical Officer

ImCheck’s first clinical trial starting in 2020

ImCheck is in a unique position with its lead first-in-class antibody rapidly progressing towards the clinic followed by a robust pipeline of exciting antibody discovery programs addressing novel targets in immuno-oncology and auto-immunity.